Valeant plans to acquire ‘female Viagra’ Addyi drugmaker Sprout for $1bn
Canada-based Valeant Pharmaceuticals International is reportedly planning to acquire US-based ‘female Viagra’ Addyi drugmaker Sprout Pharmaceuticals for around $1bn.
Go deeper with GlobalData
Under the deal, Valeant is expected to pay $500m upfront and the remaining amount the next year, reported The Wall Street Journal.
Sprout just received approval from the US Food and Drug Administration (FDA) for its Addyi (flibanserin 100mg) to treat acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women.
Mayo Clinic researchers reprogramme cancer cells back to normal
Researchers from Mayo Clinic in the US have discovered a new way to reprogramme cancer cells back to normal, minimising the tumour growth.
According to Mayo Clinic Florida campus department of cancer biology chair and study senior investigator Dr Panos Anastasiadis, the finding represents, ‘an unexpected new biology that provides the code, the software for turning off cancer’.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe researchers discovered a glue that interacts with the microprocessor and plays a crucial role in the production of molecules called microRNAs (miRNAs), which organise whole cellular programmes through simultaneously regulating expression of a group of genes.
Sprout’s Addyi obtains FDA approval to treat sexual dysfunction in women
Sprout Pharmaceuticals obtained approval from the US Food and Drug Administration (FDA) for its Addyi (flibanserin 100mg) to treat acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women.
HSDD is a persistent absence of sexual thoughts, responsiveness and willingness to involve in sexual activity. While acquired HSDD pertains to HSDD that develops in a patient who previously had no problems with sexual desire.
Addyi is a once-daily and non-hormonal pill that is claimed to be the first and only FDA-approved treatment for HSDD, a common form of female sexual dysfunction.
Shire offers $30bn to acquire drugmaker Baxalta
Specialty biopharmaceutical firm Shire made an offer of around $30bn to acquire Baxalta, a drugmaker subsidiary of Baxter.
Shire has proposed to pay $45.23 per Baxalta share, representing a 36% premium to its stock price on 3 August.
Baxalta has confirmed that it received highly conditional and unsolicited proposal from Shire to purchase all of its outstanding common shares in an all-stock transaction.
Celgene acquires biopharmaceutical firm Receptos for $7.2bn
US-based Celgene completed the acquisition of biopharmaceutical firm Receptos, for $7.2bn.
Under the deal, Celgene has paid $232.00 per share in cash to the stockholders of Receptos, which is expected to expand the firm’s inflammation and immunology (I&I) portfolio.
Receptos is involved in developing therapeutic candidates for the treatment of immune and metabolic diseases.
GSK shuts down North Carolina facility after detecting Legionnaire’s bacteria
GlaxoSmithKline (GSK) shutdown its pharmaceutical manufacturing facility in Zebulon of North Carolina, US, after detecting the bacteria that causes Legionnaire’s disease.
The company found the bacteria at the factory’s self-standing cooling tower, which is a standalone structure that will not come in contact with any products.
Legionnaire’s disease is a form of atypical pneumonia caused by any species of Gram-negative aerobic bacteria belonging to the genus Legionella.
Novo Nordisk to develop $2bn new production facilities in US and Denmark
Healthcare firm Novo Nordisk unveiled plans to invest around $2bn to develop new production facilities in the US and Denmark, in a bid to meet the increasing demand for its diabetes medicines across the globe.
The company will invest the amount over the next five years to build the new facilities in Clayton of the US and Måløv of Denmark.
Clayton facilities will be involved in the production of active pharmaceutical ingredients (API) for both oral semaglutide and a range of the firm’s current and future GLP-1 and insulin products.
Boehringer and Circuit partner to develop new medicines for obesity
Boehringer Ingelheim entered a new three-year collaboration with Circuit Therapeutics to develop novel medicines to treat obesity and associated diseases.
Under the deal, the firms will use Circuit’s proprietary optogenetics technology platform in development of new treatments.
Boehringer Ingelheim research and non-clinical development senior corporate vice-president Dr Michel Pairet said: “Boehringer Ingelheim is excited about the potential of the optogenetics technology platform developed by Circuit and wants to carry on the success already achieved in the area of neurology into the area of metabolism.”
